AI assistant
KKR & Co. Inc. — Director's Dealing 2021
Feb 17, 2021
10262_dirs_2021-02-17_a921f2a8-6d16-4951-88f4-d22eccbfe6ed.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-02-17
Reporting Person: KKR Genetic Disorder L.P. (N/A)
Reporting Person: KKR Genetic Disorder GP LLC (N/A)
Reporting Person: KKR Group Partnership L.P. (N/A)
Reporting Person: KKR Group Holdings Corp. (N/A)
Reporting Person: KKR & Co. Inc. (N/A)
Reporting Person: KKR Management LLP (N/A)
Reporting Person: KRAVIS HENRY R (N/A)
Reporting Person: ROBERTS GEORGE R (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-17 | Common Stock | S | 3450000 | $60.4688 | Disposed | 31060971 | Indirect |
Footnotes
F1: This amount represents the $62.50 secondary public offering price per share of common stock of BridgeBio Pharma, Inc. ("Common Stock") less the underwriting discount of $2.03125 per share for shares sold pursuant to an underwritten public offering
F2: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.
F3: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.